10/08/2018
Press release
BioDiscovery

Cambridge, UK, 10 August 2018. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion of a $84 million (£65 million) Series B financing following high interest from investors. The financing, which was significantly oversubscribed, was led by Andera Partners (formerly EdRIP) and LSP (Life Sciences Partners), with participation by additional new investors Pfizer Ventures and Novartis Venture Fund (NVF). Artios’ existing shareholders Arix Bioscience, SV Health Investors, M Ventures, IP Group plc and AbbVie Ventures also participated in the fundraise.

To read the full press release of Artios Pharma, click here.

Contact us


I am a business person
I am an investor
Other
Surname & given name :
Company :
Telephone :
E-mail :
My message is :